These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 34937388

  • 1. Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.
    Furtado JD, Ruotolo G, Nicholls SJ, Dullea R, Carvajal-Gonzalez S, Sacks FM.
    Arterioscler Thromb Vasc Biol; 2022 Feb; 42(2):227-237. PubMed ID: 34937388
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
    Johns DG, Duffy J, Fisher T, Hubbard BK, Forrest MJ.
    Drugs; 2012 Mar 05; 72(4):491-507. PubMed ID: 22356288
    [Abstract] [Full Text] [Related]

  • 4. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
    Nicholls SJ, Ray KK, Ballantyne CM, Beacham LA, Miller DL, Ruotolo G, Nissen SE, Riesmeyer JS, ACCENTUATE Investigators.
    Atherosclerosis; 2017 Jun 05; 261():12-18. PubMed ID: 28412650
    [Abstract] [Full Text] [Related]

  • 5. HDL metabolism and CETP inhibition.
    Barkowski RS, Frishman WH.
    Cardiol Rev; 2008 Jun 05; 16(3):154-62. PubMed ID: 18414186
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
    Reyes-Soffer G, Millar JS, Ngai C, Jumes P, Coromilas E, Asztalos B, Johnson-Levonas AO, Wagner JA, Donovan DS, Karmally W, Ramakrishnan R, Holleran S, Thomas T, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Liu Y, Lassman ME, Gutstein DE, Rader DJ, Ginsberg HN.
    Arterioscler Thromb Vasc Biol; 2016 May 05; 36(5):994-1002. PubMed ID: 26966279
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
    Teramoto T, Takeuchi M, Morisaki Y, Ruotolo G, Krueger KA.
    Am J Cardiol; 2014 Jun 15; 113(12):2021-9. PubMed ID: 24786356
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.
    Nicholls SJ, Ruotolo G, Brewer HB, Kane JP, Wang MD, Krueger KA, Adelman SJ, Nissen SE, Rader DJ.
    J Am Coll Cardiol; 2015 Nov 17; 66(20):2201-2210. PubMed ID: 26564598
    [Abstract] [Full Text] [Related]

  • 13. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
    Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE.
    Circulation; 2008 Dec 09; 118(24):2506-14. PubMed ID: 19029466
    [Abstract] [Full Text] [Related]

  • 14. Evacetrapib: Another CETP Inhibitor for Dyslipidemia With No Clinical Benefit.
    Eyvazian VA, Frishman WH.
    Cardiol Rev; 2017 Dec 09; 25(2):43-52. PubMed ID: 28099220
    [Abstract] [Full Text] [Related]

  • 15. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
    Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE.
    JAMA; 2011 Nov 16; 306(19):2099-109. PubMed ID: 22089718
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition.
    Kettunen J, Holmes MV, Allara E, Anufrieva O, Ohukainen P, Oliver-Williams C, Wang Q, Tillin T, Hughes AD, Kähönen M, Lehtimäki T, Viikari J, Raitakari OT, Salomaa V, Järvelin MR, Perola M, Davey Smith G, Chaturvedi N, Danesh J, Di Angelantonio E, Butterworth AS, Ala-Korpela M.
    PLoS Biol; 2019 Dec 16; 17(12):e3000572. PubMed ID: 31860674
    [Abstract] [Full Text] [Related]

  • 18. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
    Yamashita S, Ruscica M, Macchi C, Corsini A, Matsuzawa Y, Sirtori CR.
    Atherosclerosis; 2018 Nov 16; 278():286-298. PubMed ID: 30347344
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia.
    Teramoto T, Kiyosue A, Iimura T, Takita Y, Riesmeyer JS, Murakami M.
    Circ J; 2017 Dec 25; 82(1):183-191. PubMed ID: 28768921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.